sunitinib aqvida 50 mg hartkapseln
aqvida gmbh (8135745) - hartkapsel - 50 mg sunitinib
sunitinib aqvida 25 mg hartkapseln
aqvida gmbh (8135745) - hartkapsel - 25 mg sunitinib
sunitinib aqvida 12,5 mg hartkapseln
aqvida gmbh (8135745) - hartkapsel - 12,5 mg sunitinib
sutent
pfizer limited - sunitinib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - antineoplastische mittel - gastrointestinal stromal tumour (gist)sutent is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib mesilate treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sutent is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sutent is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours with disease progression in adults. experience with sutent as first-line treatment is limited (see section 5.
sunitinib egis 12,5 mg hartkapsel
egis gyógyszergyár zrt. (3332760) - sunitinibcyclamat - hartkapsel - 12,5 mg - sunitinibcyclamat (46316) 18,125 milligramm
sunitinib egis 50 mg hartkapseln
egis gyógyszergyár zrt. (3332760) - sunitinibcyclamat - hartkapsel - 50 mg - sunitinibcyclamat (46316) 72,5 milligramm
sunitinib egis 25 mg hartkapseln
egis gyógyszergyár zrt. (3332760) - sunitinibcyclamat - hartkapsel - 25 mg - sunitinibcyclamat (46316) 36,25 milligramm
sunitinib sandoz 12,5 mg - hartkapseln
sandoz gmbh - sunitinib -
sunitinib sandoz 25 mg - hartkapseln
sandoz gmbh - sunitinib -
sunitinib sandoz 50 mg - hartkapseln
sandoz gmbh - sunitinib -